TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies
Farooqi A.A. Turgambayeva A. Kamalbekova G. Suleimenova R. Latypova N. Ospanova S. Ospanova D. Abdikadyr Z. Zhussupov S.
December 2024Multidisciplinary Digital Publishing Institute (MDPI)
Medicina (Lithuania)
2024#60Issue 12
Cancer is a therapeutically challenging and genomically complicated disease. Pioneering studies have uncovered multifaceted aspects of cancer, ranging from intra- and inter-tumor heterogeneity, drug resistance, and genetic/epigenetic mutations. Loss of apoptosis is another critical aspect that makes cancer cells resistant to death. A substantial fraction of mechanistic information gleaned from cutting-edge studies has enabled researchers to develop near-to-complete resolution of the apoptotic pathway. Within the exciting frontiers of apoptosis, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) has garnered phenomenal appreciation by interdisciplinary researchers principally because of its unique capability to target cancer cells. TRAIL-based monotherapies and combinatorial therapies have reached phase II and phase III clinical trials. Rapidly upgrading the list of clinical trials substantiates the clinically valuable role of TRAIL-based therapeutics in cancer therapy. However, there is a growing concern about the poor bioavailability and rapid clearance of TRAIL-based therapeutics. Excitingly, the charismatic field of nanotechnology offers solutions for different problems, and we have witnessed remarkable breakthroughs in the efficacy of TRAIL-based therapeutics using nanotechnological approaches. In this review, we have attempted to provide a summary about different nanotechnologically assisted delivery methods for TRAIL-based therapeutics in cell culture studies and animal model studies for the inhibition/prevention of cancer.
apoptosis , cell signaling , metastasis , nano-formulations , nanotechnology , TRAIL , xenografted mice
Text of the article Перейти на текст статьи
Department of Molecular Oncology, Institute of Biomedical and Genetic Engineering (IBGE), Islamabad, 44090, Pakistan
Department of Public Health and Management, Astana Medical University, Astana, 010000, Kazakhstan
Department of Family Medicine, Astana Medical University, Astana, 010000, Kazakhstan
Department of Public Health and Hygiene, Astana Medical University, Astana, 010000, Kazakhstan
Faculty of Medicine and Healthcare, Al-Farabi Kazakh National University, 71 Al-Farabi Ave, Almaty, 050040, Kazakhstan
Department of Biostatistics, Bioinformatics and Information Technologies, Astana Medical University, Astana, 010000, Kazakhstan
Department of Surgery, Semey Medical University, Semey, 071400, Kazakhstan
Department of Molecular Oncology
Department of Public Health and Management
Department of Family Medicine
Department of Public Health and Hygiene
Faculty of Medicine and Healthcare
Department of Biostatistics
Department of Surgery
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026